Abstract
Background: The prevalence of Type 2 Diabetes Mellitus (T2DM) is increasing worldwide; this is stimulating more research into the optimal management of this disease. Cardiovascular Disease (CVD) remains the commonest cause of death in individuals with T2DM. Besides hyperglycaemia, an explanation for the increased mortality in this population is the increased prevalence of comorbidities, such as hypertension and dyslipidaemia. Recent population-based studies described a prevalence of hypertension >80% in patients with T2DM. In the last decade new classes of antidiabetic medications have been developed that are effective not only for the management of hyperglycaemia and but also for tailoring treatment according to individual needs and characteristics. Regulatory authorities demand the new antidiabetic medications to be examined for Cardiovascular (CV) safety. Interestingly it has been shown, mainly through CV safety trials, that some new antidiabetic medications not only have glucose lowering effects, but also Blood Pressure (BP) lowering effects, contributing to CV risk reduction.
Conclusion: This review considers the effect of older and newer antidiabetic medications on BP in patients with T2DM.
Keywords: Type 2 diabetes mellitus, cardiovascular disease, blood pressure, antidiabetic medications, CV, CVD.
Current Vascular Pharmacology
Title:Antidiabetic Drugs as Antihypertensives: New Data on the Horizon
Volume: 16 Issue: 1
Author(s): Vassiliki Mamakou, Ioanna Eleftheriadou, Niki Katsiki, Konstantinos Makrilakis, Konstantinos Tsioufis and Nikolaos Tentolouris*
Affiliation:
- First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens,Greece
Keywords: Type 2 diabetes mellitus, cardiovascular disease, blood pressure, antidiabetic medications, CV, CVD.
Abstract: Background: The prevalence of Type 2 Diabetes Mellitus (T2DM) is increasing worldwide; this is stimulating more research into the optimal management of this disease. Cardiovascular Disease (CVD) remains the commonest cause of death in individuals with T2DM. Besides hyperglycaemia, an explanation for the increased mortality in this population is the increased prevalence of comorbidities, such as hypertension and dyslipidaemia. Recent population-based studies described a prevalence of hypertension >80% in patients with T2DM. In the last decade new classes of antidiabetic medications have been developed that are effective not only for the management of hyperglycaemia and but also for tailoring treatment according to individual needs and characteristics. Regulatory authorities demand the new antidiabetic medications to be examined for Cardiovascular (CV) safety. Interestingly it has been shown, mainly through CV safety trials, that some new antidiabetic medications not only have glucose lowering effects, but also Blood Pressure (BP) lowering effects, contributing to CV risk reduction.
Conclusion: This review considers the effect of older and newer antidiabetic medications on BP in patients with T2DM.
Export Options
About this article
Cite this article as:
Mamakou Vassiliki , Eleftheriadou Ioanna , Katsiki Niki , Makrilakis Konstantinos , Tsioufis Konstantinos and Tentolouris Nikolaos*, Antidiabetic Drugs as Antihypertensives: New Data on the Horizon, Current Vascular Pharmacology 2018; 16 (1) . https://dx.doi.org/10.2174/1570161115666171010122332
DOI https://dx.doi.org/10.2174/1570161115666171010122332 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial from Editor-in-Chief: Amniotic Pulmonary Embolism and the Respiratory System: Management Trends and Future Options
Current Respiratory Medicine Reviews Clinical Experience with Specific COX-2 Inhibitors in Arthritis
Current Pharmaceutical Design Why is the Inhibition of the Renin-Angiotensin System Effective for Preventing Cardiac Events in Patients with Coronary Risk Factors or Coronary Artery Disease?
Current Cardiology Reviews MicroRNAs and Physical Activity
MicroRNA Subject Index to Volume 1
Current Vascular Pharmacology Recent Trends on the Use of Nanoparticles for Nitric Oxide Delivery in Antimicrobial Applications
Drug Delivery Letters Antiangiogenic Drugs in the Treatment of Advanced Epithelial Ovarian Cancer
Anti-Cancer Agents in Medicinal Chemistry Synthetic Hammerhead Ribozymes as Therapeutic Tools to Control Disease Genes
Current Gene Therapy Vascular Calcifications in Chronic Kidney Disease: Are There New Treatments?
Current Vascular Pharmacology Irbesartan: Second Generation of ARB as Metabosartan
Current Hypertension Reviews Role of Perindopril in the Prevention of Stroke
Recent Patents on Cardiovascular Drug Discovery Sleep in Pediatric Pulmonary Diseases
Current Respiratory Medicine Reviews Plasma Angiotensin-(1-7) is a Potential Biomarker for Alzheimer’s Disease
Current Neurovascular Research Advances in the Pharmacologic Treatment of Hepatocellular Carcinoma
Current Clinical Pharmacology The Mechanism in Gastric Cancer Chemoprevention by Allicin
Anti-Cancer Agents in Medicinal Chemistry p38 MAP Kinase Mediated Proteoglycan Synthesis as a Target for the Prevention of Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Effect of the NMDA-Receptor Antagonist Dextromethorphan in Infant Rat Pneumococcal Meningitis
Current Drug Metabolism Cardiac and Muscular Involvement in Idiopathic Inflammatory Myopathies: Noninvasive Diagnostic Assessment and the Role of Cardiovascular and Skeletal Magnetic Resonance Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Chemistry-based Design of Inhibitors for Carboxypeptidase A
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Food, Nutrition & Agriculture